These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

633 related items for PubMed ID: 15049885

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial.
    Greenspan SL, Parker RA, Ferguson L, Rosen HN, Maitland-Ramsey L, Karpf DB.
    J Bone Miner Res; 1998 Sep; 13(9):1431-8. PubMed ID: 9738515
    [Abstract] [Full Text] [Related]

  • 4. [Alendronate in postmenopausal women with osteopenia and osteoporosis: effects on bone mineral density during treatment and after withdrawal].
    Jiang Y, Li M, Xia W, Xing X, Yu W, Tian J, Meng X, Zhou X.
    Zhonghua Yi Xue Za Zhi; 2002 Sep 25; 82(18):1254-6. PubMed ID: 12425805
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. A comparison of the effect of alendronate and risedronate on bone mineral density in postmenopausal women with osteoporosis: 24-month results from FACTS-International.
    Reid DM, Hosking D, Kendler D, Brandi ML, Wark JD, Marques-Neto JF, Weryha G, Verbruggen N, Hustad CM, Mahlis EM, Melton ME.
    Int J Clin Pract; 2008 Apr 25; 62(4):575-84. PubMed ID: 18324951
    [Abstract] [Full Text] [Related]

  • 7. [Effect of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in Chinese postmenopausal women with osteoporosis].
    Liu JL, Zhu HM, Huang QR, Zhang ZL, Li HL, Qin YJ, Zhang Y, Wei DL, Lu JH, Liu H, Chen XP, Liu YJ, Ekangaki A, Zheng YM, Diez-Perez A, Harpe K.
    Zhonghua Yi Xue Za Zhi; 2004 Feb 17; 84(4):269-73. PubMed ID: 15059505
    [Abstract] [Full Text] [Related]

  • 8. Effects of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in Chinese postmenopausal women with osteoporosis: a multi-center, randomized, placebo-controlled clinical trial.
    Liu JL, Zhu HM, Huang QR, Zhang ZL, Li HL, Qin YJ, Zhang Y, Wei DL, Lu JH, Liu H, Chen XP, Liu YJ, Ekangaki A, Zheng YM, Diez-Perez A, Harper K.
    Chin Med J (Engl); 2004 Jul 17; 117(7):1029-35. PubMed ID: 15265377
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Comparison of alendronate and raloxifene in postmenopausal women with osteoporosis.
    Sanad Z, Ellakwa H, Desouky B.
    Climacteric; 2011 Jun 17; 14(3):369-77. PubMed ID: 21254911
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial.
    Deal C, Omizo M, Schwartz EN, Eriksen EF, Cantor P, Wang J, Glass EV, Myers SL, Krege JH.
    J Bone Miner Res; 2005 Nov 17; 20(11):1905-11. PubMed ID: 16234962
    [Abstract] [Full Text] [Related]

  • 14. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.
    Gallagher JC, Rosen CJ, Chen P, Misurski DA, Marcus R.
    Bone; 2006 Dec 17; 39(6):1268-75. PubMed ID: 16884968
    [Abstract] [Full Text] [Related]

  • 15. Changes in bone markers after once-weekly low-dose alendronate in postmenopausal women with moderate bone loss.
    Choi HJ, Im JA, Kim SH.
    Maturitas; 2008 Jun 20; 60(2):170-6. PubMed ID: 18572334
    [Abstract] [Full Text] [Related]

  • 16. Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis.
    Rizzoli R, Greenspan SL, Bone G, Schnitzer TJ, Watts NB, Adami S, Foldes AJ, Roux C, Levine MA, Uebelhart B, Santora AC, Kaur A, Peverly CA, Orloff JJ, Alendronate Once-Weekly Study Group.
    J Bone Miner Res; 2002 Nov 20; 17(11):1988-96. PubMed ID: 12412806
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Effect of alendronate on bone mineral density and bone turnover in Thai postmenopausal osteoporosis.
    Chailurkit LO, Jongjaroenprasert W, Rungbunnapun S, Ongphiphadhanakul B, Sae-tung S, Rajatanavin R.
    J Bone Miner Metab; 2003 Nov 20; 21(6):421-7. PubMed ID: 14586800
    [Abstract] [Full Text] [Related]

  • 19. Treatment with alendronate plus calcium, alendronate alone, or calcium alone for postmenopausal low bone mineral density.
    Bonnick S, Broy S, Kaiser F, Teutsch C, Rosenberg E, DeLucca P, Melton M.
    Curr Med Res Opin; 2007 Jun 20; 23(6):1341-9. PubMed ID: 17594775
    [Abstract] [Full Text] [Related]

  • 20. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
    McClung M, Recker R, Miller P, Fiske D, Minkoff J, Kriegman A, Zhou W, Adera M, Davis J.
    Bone; 2007 Jul 20; 41(1):122-8. PubMed ID: 17468062
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.